+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Osteoarthritis Drug"

Osteoarthritis - Pipeline Review, H2 2020 - Product Thumbnail Image

Osteoarthritis - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 384 Pages
  • Global
From
US Osteoarthritis Market and Competitive Landscape - 2022 - Product Thumbnail Image

US Osteoarthritis Market and Competitive Landscape - 2022

  • Report
  • August 2022
  • United States
From
From
From
Market Spotlight: Osteoarthritis and Osteoarthritis Pain - Product Thumbnail Image

Market Spotlight: Osteoarthritis and Osteoarthritis Pain

  • Report
  • February 2021
  • 48 Pages
  • Global
From
Loading Indicator

The Osteoarthritis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Osteoarthritis is a degenerative joint disease that affects millions of people worldwide. It is characterized by the breakdown of cartilage in the joints, leading to pain, stiffness, and decreased mobility. Treatment for osteoarthritis typically involves a combination of lifestyle changes, physical therapy, and medications. Common medications used to treat osteoarthritis include non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and disease-modifying antirheumatic drugs (DMARDs). The Osteoarthritis Drug market is highly competitive, with a variety of companies offering products to treat the condition. Some of the major players in the market include Pfizer, Merck, Novartis, AbbVie, and Johnson & Johnson. Other companies such as Amgen, Eli Lilly, and Bristol-Myers Squibb also offer products for the treatment of osteoarthritis. Show Less Read more